Michael Aboud

2.8k citations

31 papers · 1.1k indexed · 1 hit paper · h-index 13

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 21
- HIV Research and Treatment 21
Infectious Diseases 28
- HIV/AIDS drug development and treatment 28
- HIV/AIDS Research and Interventions 13

Co-authors: Brian Wynne (13 shared papers)Martin Gartland (9 shared papers)Mark Underwood (8 shared papers)Kimberly Y. Smith (11 shared papers)Lesley Kahl (4 shared papers)Kati Vandermeulen (4 shared papers)Cynthia Brinson (2 shared papers)Elizabeth A. Blair (3 shared papers)
Journals: Antiviral Therapy (4 papers)Open Forum Infectious Diseases (4 papers)Journal of Infection and Public Health (3 papers)Clinical Infectious Diseases (2 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (2 papers)
Partner nations: United Kingdom United States Spain

In The Last Decade

Michael Aboud

30 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies 2018 · 243 citations

Peers

Countries citing papers authored by Michael Aboud

Since Specialization

Citations

This map shows the geographic impact of Michael Aboud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Aboud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Aboud more than expected).

Fields of papers citing papers by Michael Aboud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Aboud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Aboud. The network helps show where Michael Aboud may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Aboud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Aboud Line = papers co-authored together Michael Aboud links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies The Lancet ·Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre‐Marie Girard, Lesley Kahl, Elizabeth A. Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, K. Smith, Martin Gartland, Michael Aboud Hit paper breakdown →	2018	243
2	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study Clinical Infectious Diseases ·Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Maria Cláudia Nascimento, Keith A. Pappa, Ruolan Wang, Jonathan Wright, Allan R. Tenorio, Brian Wynne, Michael Aboud, Martin Gartland, Kimberly Y. Smith	2020	171
3	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial The Lancet Infectious Diseases ·Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, Maria Cláudia Nascimento, Yogesh Punekar, Martin Gartland, Kimberly Y. Smith	2019	104
4	Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study Antiviral Therapy ·Benoît Trottier, Jordan E. Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud	2016	82
5	Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies The Lancet HIV ·Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R. Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley Kahl, Elizabeth A. Blair, Kimberly K. Adkison, Mark Underwood, Jessica Matthews, Brian Wynne, Kati Vandermeulen, Martin Gartland, Kimberly Y. Smith	2019	77
6	Psychiatric Symptoms in Patients Receiving Dolutegravir JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anna Fettiplace, Chris Stainsby, Alan Winston, Naomi Givens, Sarah Puccini, Vani Vannappagari, Ricky Hsu, Jennifer S Fusco, Romina Quercia, Michael Aboud, Lloyd Curtis	2016	75
7	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial Clinical Infectious Diseases ·Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Jean Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Peter A. Leone, Keith A. Pappa, Ruolan Wang, Jonathan Wright, Nisha George, Brian Wynne, Michael Aboud, Jean van Wyk, Kimberly Y. Smith	2022	69
8	Insulin resistance and HIV infection: a review International Journal of Clinical Practice ·Michael Aboud, Ali Elgalib, Ranjababu Kulasegaram, B Peters	2007	51
9	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study International Journal of Clinical Practice ·Michael Aboud, Ali Elgalib, Laura W. Pomeroy, George Panayiotakopoulos, Elias Skopelitis, Ranjababu Kulasegaram, C. Dimian, Fiona Lampe, Alastair Duncan, Anthony S. Wierzbicki, Barry Peters	2010	45
10	Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health AIDS ·Grace A. McComsey, Sergio Lupo, David Parks, Mónica Coronado Poggio, Joseph de Wet, Lesley Kahl, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Martin Gartland, Michael Cupo, Michael Aboud	2017	43
11	The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study Current Medical Research and Opinion ·Ali Elgalib, Michael Aboud, Ranjababu Kulasegaram, C. Dimian, Alastair Duncan, Anthony S. Wierzbicki, Barry Peters	2010	20
12	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joseph J. Eron, Chien‐Ching Hung, Jean‐Guy Baril, Jihad Slim, Vicenç Falcó, Johannes R. Bogner, Franco Maggiolo, Anthony Mills, Jörg Sievers, Choy Man, Rimgaile Urbaityte, Mark Underwood, Allan R. Tenorio, Keith A. Pappa, Brian Wynne, Justin Koteff, Martin Gartland, Kimberly Y. Smith, Michael Aboud	2020	15
13	Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review Antiviral Therapy ·Vani Vannappagari, Leigh Ragone, Cassidy Henegar, Jean van Wyk, Dannae Brown, James F. Demarest, Romina Quercia, Marty St. Clair, Mark Underwood, José M. Gatell, Annemiek de Ruiter, Michael Aboud	2018	13
14	Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups Open Forum Infectious Diseases ·Debbie Hagins, Craig Dietz, Mamta K. Jain, Cornelius Van Dam, Indira Brar, Choy Man, Jiangxiu Zhou, Annie Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y. Smith	2016	10
15	P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study Journal of the International AIDS Society ·Pedro Cahn, Jaime Andrade‐Villanueva, Carlos Beltrán, Tâmara Newman, David Dorey, Dannae Brown, Isidoro Prudente, Sandy Griffith, Michael Aboud, Carlos Fernando de Oliveira	2015	9
16	Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database Therapeutic Advances in Drug Safety ·Ricky Hsu, Jennifer S Fusco, Cassidy Henegar, Karam Mounzer, Michael Wohlfeiler, Vani Vannappagari, Michael Aboud, Lloyd Curtis, Gregory Fusco	2018	7
17	Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy Journal of Antimicrobial Chemotherapy ·Jason Gillman, Patrick Janulis, Roy M. Gulick, Carole L. Wallis, Baiba Berzins, Roger Bedimo, Kimberly Y. Smith, Michael Aboud, Babafemi Taiwo	2019	7
18	900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study) Open Forum Infectious Diseases ·Olayemi Osiyemi, Faïza Ajana, Fiona Bisshop, Christoph Stephan, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Keith A. Pappa, Ruolan Wang, Peter A. Leone, Jonathan Wright, Brian Wynne, Jean A van Wyk, Michael Aboud, Kimberly Y. Smith	2021	7
19	Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) Journal of Infection and Public Health ·Jean van Wyk, F. Ajana, Fiona Bisshop, (unknown), Y. Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, M. C. Nascimento, Keith A. Pappa, Rachel Y. Wang, Jackson Wright, A. Tenorio, Brian Wynne, Michael Aboud, Martin Gartland, Kate Smith, Y. El-Bahy	2020	6
20	Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study Journal of Infection and Public Health ·Michael Aboud, Richard Kaplan, Johannes Lombaard, F. Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, M. C. Nascimento, Martin Gartland, K. Smith, C. R. Steinhart, José M. Gatell	2019	5

About Michael Aboud

Michael Aboud is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Hepatology and Endocrinology, Diabetes and Metabolism, having authored 31 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers), HIV/AIDS Research and Interventions (13 papers), HIV-related health complications and treatments (11 papers), Hepatitis C virus research (6 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers) and Lipoproteins and Cardiovascular Health (1 paper). The work is most often cited by research in Virology (703 citations), Infectious Diseases (950 citations), Emergency Medicine (407 citations), Hepatology (55 citations) and Epidemiology (172 citations). Michael Aboud has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Brian Wynne, Martin Gartland, Mark Underwood, Kimberly Y. Smith, Lesley Kahl, Kati Vandermeulen, Cynthia Brinson, Elizabeth A. Blair, Ali Elgalib and Ranjababu Kulasegaram. Their work appears in journals such as Antiviral Therapy, Open Forum Infectious Diseases, Journal of Infection and Public Health, Clinical Infectious Diseases and JAIDS Journal of Acquired Immune Deficiency Syndromes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact